CN111990462A - Infant formula containing protein composition and preparation method thereof - Google Patents
Infant formula containing protein composition and preparation method thereof Download PDFInfo
- Publication number
- CN111990462A CN111990462A CN202010831837.6A CN202010831837A CN111990462A CN 111990462 A CN111990462 A CN 111990462A CN 202010831837 A CN202010831837 A CN 202010831837A CN 111990462 A CN111990462 A CN 111990462A
- Authority
- CN
- China
- Prior art keywords
- protein
- casein
- whey protein
- parts
- content
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 114
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 113
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 235000018102 proteins Nutrition 0.000 claims abstract description 112
- 239000000843 powder Substances 0.000 claims abstract description 80
- 102000007544 Whey Proteins Human genes 0.000 claims abstract description 77
- 108010046377 Whey Proteins Proteins 0.000 claims abstract description 77
- 235000021119 whey protein Nutrition 0.000 claims abstract description 74
- 102000011632 Caseins Human genes 0.000 claims abstract description 70
- 108010076119 Caseins Proteins 0.000 claims abstract description 70
- 239000005018 casein Substances 0.000 claims abstract description 40
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 40
- 235000021240 caseins Nutrition 0.000 claims abstract description 40
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 34
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 34
- 235000013336 milk Nutrition 0.000 claims abstract description 28
- 239000008267 milk Substances 0.000 claims abstract description 28
- 210000004080 milk Anatomy 0.000 claims abstract description 28
- 235000021247 β-casein Nutrition 0.000 claims abstract description 28
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 23
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 22
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 22
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 22
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 22
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 22
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 22
- 108010071421 milk fat globule Proteins 0.000 claims abstract description 22
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 22
- 108010001441 Phosphopeptides Proteins 0.000 claims abstract description 20
- 239000002671 adjuvant Substances 0.000 claims abstract 2
- 235000020185 raw untreated milk Nutrition 0.000 claims description 31
- 239000003921 oil Substances 0.000 claims description 26
- 235000019198 oils Nutrition 0.000 claims description 26
- 239000000463 material Substances 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000003623 enhancer Substances 0.000 claims description 16
- 235000016709 nutrition Nutrition 0.000 claims description 16
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 claims description 15
- 230000035764 nutrition Effects 0.000 claims description 13
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 12
- 235000013305 food Nutrition 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 12
- 229930003231 vitamin Natural products 0.000 claims description 12
- 235000013343 vitamin Nutrition 0.000 claims description 12
- 239000011782 vitamin Substances 0.000 claims description 12
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 10
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 10
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 10
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 10
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 9
- 239000003240 coconut oil Substances 0.000 claims description 9
- 235000019864 coconut oil Nutrition 0.000 claims description 9
- 235000005687 corn oil Nutrition 0.000 claims description 9
- 239000002285 corn oil Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 235000020238 sunflower seed Nutrition 0.000 claims description 9
- 235000013311 vegetables Nutrition 0.000 claims description 9
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims description 8
- 235000018927 edible plant Nutrition 0.000 claims description 8
- 239000011265 semifinished product Substances 0.000 claims description 8
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 7
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 6
- 235000021342 arachidonic acid Nutrition 0.000 claims description 6
- 229940114079 arachidonic acid Drugs 0.000 claims description 6
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 6
- 239000001509 sodium citrate Substances 0.000 claims description 6
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 6
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 5
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 5
- 235000019743 Choline chloride Nutrition 0.000 claims description 5
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 5
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 5
- 229960002685 biotin Drugs 0.000 claims description 5
- 235000020958 biotin Nutrition 0.000 claims description 5
- 239000011616 biotin Substances 0.000 claims description 5
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 5
- 229960003178 choline chloride Drugs 0.000 claims description 5
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 claims description 5
- 229940108925 copper gluconate Drugs 0.000 claims description 5
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 5
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims description 5
- 239000004222 ferrous gluconate Substances 0.000 claims description 5
- 235000013924 ferrous gluconate Nutrition 0.000 claims description 5
- 229960001645 ferrous gluconate Drugs 0.000 claims description 5
- 229960000304 folic acid Drugs 0.000 claims description 5
- 235000019152 folic acid Nutrition 0.000 claims description 5
- 239000011724 folic acid Substances 0.000 claims description 5
- 229960000367 inositol Drugs 0.000 claims description 5
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 5
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims description 5
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 5
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 5
- 229940055726 pantothenic acid Drugs 0.000 claims description 5
- 235000019161 pantothenic acid Nutrition 0.000 claims description 5
- 239000011713 pantothenic acid Substances 0.000 claims description 5
- 239000011772 phylloquinone Substances 0.000 claims description 5
- 239000001103 potassium chloride Substances 0.000 claims description 5
- 235000011164 potassium chloride Nutrition 0.000 claims description 5
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000011781 sodium selenite Substances 0.000 claims description 5
- 235000015921 sodium selenite Nutrition 0.000 claims description 5
- 229960001471 sodium selenite Drugs 0.000 claims description 5
- 229960003080 taurine Drugs 0.000 claims description 5
- 239000011691 vitamin B1 Substances 0.000 claims description 5
- 239000011715 vitamin B12 Substances 0.000 claims description 5
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 239000011670 zinc gluconate Substances 0.000 claims description 5
- 235000011478 zinc gluconate Nutrition 0.000 claims description 5
- 229960000306 zinc gluconate Drugs 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 4
- 229940090949 docosahexaenoic acid Drugs 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 229940099596 manganese sulfate Drugs 0.000 claims description 4
- 239000011702 manganese sulphate Substances 0.000 claims description 4
- 235000007079 manganese sulphate Nutrition 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 239000011716 vitamin B2 Substances 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 3
- 229930003316 Vitamin D Natural products 0.000 claims description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 239000005862 Whey Substances 0.000 claims description 3
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 3
- -1 compound vitamin Chemical class 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 235000019155 vitamin A Nutrition 0.000 claims description 3
- 239000011719 vitamin A Substances 0.000 claims description 3
- 235000019166 vitamin D Nutrition 0.000 claims description 3
- 239000011710 vitamin D Substances 0.000 claims description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 229940045997 vitamin a Drugs 0.000 claims description 3
- 229940046008 vitamin d Drugs 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 235000019865 palm kernel oil Nutrition 0.000 claims description 2
- 239000003346 palm kernel oil Substances 0.000 claims description 2
- 235000019175 phylloquinone Nutrition 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- MBWXNTAXLNYFJB-LKUDQCMESA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCCC(C)CCCC(C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-LKUDQCMESA-N 0.000 claims description 2
- 229960001898 phytomenadione Drugs 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 235000020256 human milk Nutrition 0.000 abstract description 31
- 210000004251 human milk Anatomy 0.000 abstract description 31
- 238000010521 absorption reaction Methods 0.000 description 19
- 235000015097 nutrients Nutrition 0.000 description 18
- 238000011161 development Methods 0.000 description 13
- 230000001737 promoting effect Effects 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 150000003722 vitamin derivatives Chemical class 0.000 description 10
- 235000019621 digestibility Nutrition 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 102000014171 Milk Proteins Human genes 0.000 description 6
- 108010011756 Milk Proteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 235000013365 dairy product Nutrition 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000020247 cow milk Nutrition 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000011785 micronutrient Substances 0.000 description 3
- 235000013369 micronutrients Nutrition 0.000 description 3
- 235000021239 milk protein Nutrition 0.000 description 3
- 235000020200 pasteurised milk Nutrition 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 206010006956 Calcium deficiency Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 108090000746 Chymosin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 101000978703 Escherichia virus Qbeta Maturation protein A2 Proteins 0.000 description 1
- 206010016946 Food allergy Diseases 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010051606 Necrotising colitis Diseases 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940080701 chymosin Drugs 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000003298 dental enamel Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- GNOLWGAJQVLBSM-UHFFFAOYSA-N n,n,5,7-tetramethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1=C(C)C=C2C(N(C)C)CCCC2=C1C GNOLWGAJQVLBSM-UHFFFAOYSA-N 0.000 description 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000006180 nutrition needs Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1522—Inorganic additives, e.g. minerals, trace elements; Chlorination or fluoridation of milk; Organic salts or complexes of metals other than natrium or kalium; Calcium enrichment of milk
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
- A23C9/158—Milk preparations; Milk powder or milk powder preparations containing additives containing vitamins or antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/16—Agglomerating or granulating milk powder; Making instant milk powder; Products obtained thereby
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Dairy Products (AREA)
Abstract
The invention relates to infant formula milk powder, in particular to infant formula milk powder containing a protein composition and a preparation method thereof; the protein composition comprises casein, whey protein, milk fat globule membrane protein and hydrolyzed protein; wherein the mass ratio of casein to lactalbumin to milk fat globule membrane protein to hydrolyzed protein is 15-21: 11-20: 0.5-3: 4-10; the casein is A2 type beta-casein; the whey protein consists of alpha-lactalbumin and lactoferrin in a mass ratio of 10-17: 0.5-3; the hydrolyzed protein consists of hydrolyzed whey protein and casein phosphopeptides in a mass ratio of 2-8: 1-3. The invention also provides an infant formula consisting of the protein composition and an adjuvant system, wherein the composition and content of the protein in the infant formula are closer to those of breast milk; furthermore, the infant formula is more digestible and absorbable.
Description
Technical Field
The invention relates to infant formula milk powder, in particular to infant formula milk powder containing a protein composition and a preparation method thereof.
Background
The most ideal food for infants is breast milk, which can provide the infants with comprehensive and balanced nutritional ingredients, and the breast milk is rich in trace active ingredients for resisting infectious diseases, so that the risk of allergic diseases can be reduced. Under the condition of insufficient or no breast milk, the infant formula milk powder is a good substitute for the breast milk, aims to adjust the composition and proportion of nutrients on the basis of the cow milk to enable the components of the infant formula milk powder to be close to those of the breast milk, and is suitable for normal nutritional needs and digestive absorption of infants.
The protein is the material basis of all lives, is used as a carrier for absorption and transportation of other micronutrients to participate in and promote absorption and utilization of the micronutrients, is beneficial to the growth and development of infants, and has biological functions of resisting bacteria, resisting viruses, enhancing immunity and the like in certain protein compositions and degradation segments thereof. The milk protein is the most concerned breast milk component of researchers, and at present, most infant formula milk powder meets the requirement of GB 10765 national standard infant formula food for food safety that the ratio of whey protein to casein is more than 60: 40, or the composition of one or two proteins is close to that of breast milk. This is quite different from the composition of breast milk proteins. The breast milk contains more than 1000 kinds of proteins, peptides and free amino acids, and the main proteins are whey protein (including alpha-lactalbumin, beta-lactoglobulin (immunoglobulin), serum albumin, lactoferrin, osteopontin, etc., accounting for 70% of the total protein), casein (including beta-casein and kappa-casein, accounting for 30% of the total protein). Protein deep-matrixing should be close to breast milk proteins in a variety of protein compositions and contents. The effects of providing essential amino acids required by the growth and development of infants, promoting the digestion and the intake of other nutrients, enhancing the immune function, promoting the growth and the field planting of intestinal probiotics and the like are achieved, and the comfort and the effectiveness of the product on the absorption of the nutrients are further improved.
In summary, in the field of infant formula, there is still much gap in deep protein emulsification of infant formula, so that it is one of the problems to be solved at present to design and develop an infant formula containing a protein composition by referring to the data of protein composition and content of Chinese breast milk, so that the protein composition and content are closer to those of breast milk.
Disclosure of Invention
The invention provides an infant formula containing a protein composition and a preparation method thereof; the composition and content of protein in the infant formula are closer to those of breast milk; furthermore, the infant formula is more digestible and absorbable.
As a first object of the present invention, there is provided a protein composition; the protein composition can realize deep emulsification in a real sense.
In particular, the protein composition comprises casein, whey protein, milk fat globule membrane protein, and hydrolyzed protein;
wherein the mass ratio of casein to lactalbumin to milk fat globule membrane protein to hydrolyzed protein is 15-21: 11-20: 0.5-3: 4-10;
the casein is A2 type beta-casein; the lactalbumin consists of alpha-lactalbumin and lactoferrin in a mass ratio of 10-17: 0.5-3; the hydrolyzed protein consists of hydrolyzed whey protein and casein phosphopeptides in a mass ratio of 2-8: 1-3.
According to the invention, through a large amount of formula screening and process screening experiments, A2 type beta-casein, alpha-lactalbumin, milk fat globule membrane protein, hydrolyzed whey protein, lactoferrin and casein phosphopeptide are selected to be compounded to obtain a protein composition, and the dosage ratio of each component in the protein composition is further researched on the basis; the resulting protein composition is closer to the protein component of breast milk; meanwhile, the components in the composition are cooperatively compatible, so that the absorption of nutrients by a body is better facilitated; the protein composition has obvious promotion effect on the healthy growth of the babies.
Preferably, the A2 type beta-casein is added in a form including but not limited to raw milk, preferably raw milk, and the content of the A2 type beta-casein in the raw milk is 0.9-2.5%;
preferably, the alpha-lactalbumin is added in the form of whey protein powder I, and the content of the alpha-lactalbumin in the whey protein powder I is 34-70%;
preferably, the milk fat globule membrane protein is added in the form of whey protein powder II, and the content of the milk fat globule membrane protein in the whey protein powder II is 8-20%;
preferably, the hydrolyzed whey protein is added in the form of whey protein powder III, and the content of the hydrolyzed whey protein in the whey protein powder III is 52-85%;
preferably, the purity of the lactoferrin is 80% -98%;
preferably, the casein phosphopeptide has a purity of 20% to 96%.
In the present invention, when the a2 type beta-casein, alpha-lactalbumin, milk fat globule membrane protein and hydrolyzed whey protein are added to the composition in the specific form as described above, the resulting protein composition is better for digestion and absorption by the body.
The A2 type beta-casein can be added in the form of the conventional dairy products (such as raw milk, whole milk powder and the like, and raw milk is particularly ideal) in the field, and the technical effect of the invention can be realized as long as the content of the A2 type beta-casein in the dairy products is within the range of 0.9-2.5%.
Preferably, the protein composition comprises the following components in parts by weight:
the research of the invention finds that the protein composition within the content range is beneficial to the growth and development of infants, and has the functions of resisting bacteria and viruses, enhancing the immunity, promoting the absorption of mineral substances and improving the absorption comfort of organisms.
Further, the protein composition comprises the following components in parts by weight:
still further, the protein composition comprises the following components in parts by weight:
in the development process, the protein composition of the obtained composition is particularly close to that of breast milk when the components in the composition are mixed according to the weight parts, so that the composition is more favorable for the growth and development of infants.
As the best technical scheme of the invention, the protein composition comprises the following components in parts by weight:
the protein composition provided by the invention has the advantages that the protein components and the content of the composition are closer to those of breast milk by adding raw milk containing A2 type beta-casein with specific content, whey protein powder I containing alpha-lactalbumin with specific content, whey protein powder II containing milk fat globule membrane protein with specific content and lactoferrin with specific purity; and whey protein powder III containing hydrolyzed whey protein with specific content and casein phosphopeptide with specific purity are added, so that the digestion of the body and the absorption of nutrients are facilitated. The protein composition is deeply emulsified in the true sense, and has obvious promotion effect on the healthy growth of babies when being used for preparing the infant formula milk powder.
The second purpose of the invention is to provide the application of the protein composition in preparing food, health food or medicines; preferably, the food product comprises milk powder, more preferably infant formula.
A third object of the present invention is to provide an infant formula containing a protein composition; the infant formula comprises the protein composition described above.
Preferably, in the technical scheme, the weight percentage of the protein composition in the infant formula milk powder is 18-66%;
further, the weight percentage of the protein composition in the infant formula is 22-60%;
further, the protein composition is present in the infant formula in an amount of 25 to 56% (especially 30%) by weight.
Wherein the dried raw milk in the protein composition is reduced by 12%.
In order to further improve the digestion and absorption of the infant formula milk powder in the body of a baby, the invention also researches an auxiliary material system, and determines the composition of the auxiliary material system in the intensive research.
In particular, the infant formula further comprises an auxiliary material; the auxiliary materials comprise edible plant blend oil, lactose, fructo-oligosaccharide, calcium carbonate, sodium citrate, compound nutrition enhancer, arachidonic acid (namely arachidonic acid, ARA) and docosahexaenoic acid (DHA);
wherein the edible vegetable blend oil is selected from at least two of 1, 3-dioleoyl-2-palmitic acid triglyceride, soybean oil, rapeseed oil, sunflower seed oil, corn oil, palm kernel oil and coconut oil; preferably a mixture of corn oil, rapeseed oil, coconut oil and sunflower seed oil according to the weight ratio of 8-10: 7-9: 1-3: 1 (9: 8: 2: 1 is particularly ideal);
the compound nutrition enhancer comprises the following components in percentage by weight: 20-40% of compound vitamin, 30-60% of compound mineral and 10-25% of lactose.
Researches show that after the protein composition is selected and compounded with the auxiliary material system, the auxiliary material system can effectively promote the digestion and absorption of the protein composition, the protein composition and the auxiliary material system supplement each other, and the digestion and absorption capacity of the infant formula milk powder in a baby body is further improved on the basis of deep breast milk. Meanwhile, the auxiliary material system contains long-chain polyunsaturated fatty acids required by various baby organisms, and the baby in the golden period of physique development can be more favorable for the physique development of the baby.
Preferably, the infant formula comprises the following components in parts by weight:
the protein composition comprises 140-440 parts of raw milk with A2 type beta-casein content of 0.9-2.5%, 1-5 parts of lactalbumin powder I with alpha-lactalbumin content of 34-70%, 0.5-4 parts of lactalbumin powder II with milk fat globule membrane protein content of 8-20%, 0.1-3 parts of lactalbumin powder III with hydrolyzed lactalbumin content of 52-85%, 0.05-0.4 part of lactoferrin with purity of 80-98%, and 0.1-0.4 part of casein phosphopeptide with purity of 20-96%;
the edible vegetable blend oil is a mixture of corn oil, rapeseed oil, coconut oil and sunflower seed oil according to the weight ratio of 8-10: 7-9: 1-3: 1 (9: 8: 2: 1 is particularly ideal);
the compound nutrition enhancer comprises the following components in percentage by weight: 0.4 to 1.4 percent of vitamin A, 0.3 to 1.3 percent of vitamin D, 2 to 5 percent of vitamin E and K10.003-0.02 percent of vitamin B10.01 to 0.2 percent of vitamin B20.008 to 0.4 percent of vitamin B60.02-0.2 percent of vitamin B120.0001-0.001%, 10-25% of vitamin C, 0.1-1% of pantothenic acid, 0.005-0.05% of folic acid, 0.2-1% of nicotinamide, 0.0010-0.005% of biotin, 2-10% of inositol, 2-10% of taurine, 0.5-2% of L-carnitine, 5-20% of choline chloride, 5-20% of sodium chloride, 10-30% of potassium chloride, 2-15% of magnesium sulfate, 1-5% of zinc gluconate, 2-15% of ferrous gluconate, 0.1-0.6% of copper gluconate, 0.001-0.02% of potassium iodide, 0.001-0.01% of sodium selenite, 0-0.1% of manganese sulfate, 3-15% of calcium hydrogen phosphate and the balance of lactose.
Preferably, the infant formula comprises the following components in parts by weight:
wherein the protein composition comprises 150-380 parts of raw milk with A2 type beta-casein content of 0.9-2.5%, 1.5-4.5 parts of whey protein powder I with alpha-lactalbumin content of 34-70%, 1-3 parts of whey protein powder II with milk fat globule membrane protein content of 8-20%, 0.4-2.5 parts of whey protein powder III with hydrolyzed whey protein content of 52-85%, 0.1-0.3 part of lactoferrin with purity of 80-98%, and 0.15-0.4 part of casein phosphopeptide with purity of 20-96%;
the edible plant blend oil and the compound nutrition enhancer are the same as above.
Preferably, the infant formula comprises the following components in parts by weight:
wherein the protein composition comprises 170-370 parts of raw milk with A2 type beta-casein content of 0.9-2.5%, 2-4.5 parts of whey protein powder I with alpha-lactalbumin content of 34-70%, 1.5-2.5 parts of whey protein powder II with milk fat globule membrane protein content of 8-20%, 0.5-2 parts of whey protein powder III with hydrolyzed whey protein content of 52-85%, 0.15-0.3 part of lactoferrin with purity of 80-98%, and 0.15-0.3 part of casein phosphopeptide with purity of 20-96%;
the edible plant blend oil and the compound nutrition enhancer are the same as above.
As a fourth object of the present invention, there is provided a method for preparing the above infant formula, comprising the steps of:
1) mixing desalted whey powder, edible vegetable blend oil, whey protein powder I, whey protein powder II, whey protein powder III, lactose, fructo-oligosaccharide, phospholipid, calcium carbonate, sodium citrate, compound nutrition enhancer and raw milk, homogenizing, vacuum concentrating, and spray drying to obtain semi-finished product;
2) adding arachidonic acid, docosahexaenoic acid, lactoferrin and casein phosphopeptide into the semi-finished product, and mixing uniformly.
Protein is the material basis of all life, and is a high molecular substance with the most abundant content and the most functions in cell components. The protein in breast milk is an important source of amino acid, and is used as a carrier for absorption and transportation of other micronutrients to participate and promote absorption and utilization of nutrients in milk. The composition is helpful for infant growth and development, and has the function of protecting dental enamel (such as whey protein and casein). Proteins in breast milk can be divided into four major groups: namely casein, whey protein, fat globule membrane protein and cell protein, wherein the casein and the whey protein are main components. In addition, some proteins, such as lactoferrin, immunoglobulins, and some trace amounts of other proteins, also have important biological functions in the newborn's early life.
Beta-casein is the main component of casein in breast milk, and beta-casein and its hydrolysate (active polypeptide) have the functions of providing essential amino acids for human body, participating in nerve regulation, promoting nutrient absorption, etc. Beta-casein exists in A1 type (contained in cow milk) and A2 type (contained in breast milk), the difference is that the amino acid composition is different, the A2 type beta-casein is the casein type in breast milk, and the cow milk containing A2 type protein (A2 casein) has more affinity to human body and digestive system. The milk only containing A2 protein can effectively avoid the problem of intestinal inflammation caused by A1 type beta-casein protein.
Alpha-lactalbumin, which is a major component of whey protein in breast milk, has a very high nutritional value (nutritional quality) for newborns and infants, and an amino acid composition very similar to the estimated amino acid requirements and amino acid pattern for newborns. When the alpha-lactalbumin is digested in the intestinal tract of the infant, the produced polypeptide has the functions of resisting bacteria and enhancing the immunity of the infant; improving the regulation of the sleep/wake cycle of the infant, promoting mineral absorption in the infant, and relieving gastrointestinal discomfort in the infant; the recently discovered alpha-lactalbumin polymer also has the functions of resisting infection and promoting apoptosis, and the functions have important significance for protecting the intestinal health of infants.
Milk fat globule membrane proteins are a class of proteins which are low in content in breast milk and remain in lipids, including mucin, lactomucin, lactoferrin and the like, and also contain sphingomyelin, ganglioside, sialic acid, cholesterol and the like, wherein part of proteins are proved to have biological activity or functions, have the main functions of resisting bacteria and viruses, participate in the absorption of nutrients, and play an important role in a plurality of cellular reaction processes and defense mechanisms of newborns. The phospholipid in milk fat globule membrane protein is similar to breast milk in kind, and is helpful for normal development of brain and nerve.
Lactoferrin is an important active protein in breast milk. The existing population research results show that the lactoferrin can prevent and assist in treating infantile diarrhea, necrotizing enterocolitis of newborn, respiratory diseases and septicemia of newborn, and has certain effects of improving infantile anemia and promoting growth and development of the infantile anemia.
Hydrolyzed whey protein is a protein or small molecule polypeptide that is broken down into smaller fragments by certain biological techniques, thereby reducing the amount of active substances with antigens, reducing or eliminating the allergenicity of milk protein, and reducing the risk of developing milk protein allergy. The hydrolyzed whey protein can reduce the gastrointestinal burden, directly improve the digestion, absorption and utilization rate of the protein, and is very important for the growth and development of the body and the health of the body. For infants, the digestive system and other organs are still developing and in sensitive stage, and allergic reactions such as eczema, allergic rhinitis, asthma and the like are most likely to occur. The function of the fertilizer is that firstly, the fertilizer can provide nutrient substances necessary for the growth and development of human bodies; secondly, the food is easy to digest and absorb and has high utilization rate; ③ resisting allergy; fourthly, oxidation resistance is realized; fifthly, immunoregulation; sixthly, promoting the proliferation of probiotics; and promoting growth.
Casein phosphopeptide (CPP) is a polypeptide obtained by hydrolyzing cow milk casein, is proved to be capable of keeping calcium in milk in a soluble form, promoting the calcium to be absorbed by intestinal cells and ensuring that a newborn obtains a proper amount of calcium, and CPPs can improve the bioavailability of metal ions such as iron, zinc, magnesium and the like, so that the CPP is called as a peptide substance with a metal carrier function. The problem of calcium deficiency is widely regarded, and besides finding a good calcium supplement preparation, the improvement of the absorption and utilization rate of calcium in the existing diet is also one of the important methods for solving the problem of calcium deficiency.
The research of the invention finds that the deep protein mother emulsion is close to the breast milk protein in the main components and contents of the protein, thereby achieving the effects of providing essential amino acids required by the growth and development of infants, promoting the digestion and the intake of other nutrients, enhancing the immune function, promoting the growth and the permanent planting of intestinal probiotics and the like, and further improving the comfort and the effectiveness of the product on the absorption of the nutrients.
Detailed Description
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
The raw milk related in the embodiment is purchased from Harbin Wandashan Dairy cow-farming Co Ltd, and the content of A2 type beta-casein in the raw milk is 0.9-2.5%; the whey protein powder I is purchased from food materials GmbH of Arara, Denmark, and has alpha-lactalbumin content of 34-70%; the whey protein powder II is purchased from the food materials GmbH of Arara, Denmark, and has a milk fat globule membrane protein content of 8-20%; the whey protein powder III is purchased from food materials GmbH of Arara, Denmark, and the content of hydrolyzed whey protein in the whey protein powder III is 52-85%; lactoferrin was purchased from vanan boolean cheese butter company and its purity was 80% -98%; casein phosphopeptide is purchased from Guangzhou green extract biotechnology limited and has the purity of 20-96 percent.
Example 1
The present embodiment provides a protein composition, which includes the following components in parts by weight:
example 2
The present embodiment provides a protein composition, which includes the following components in parts by weight:
example 3
The present embodiment provides a protein composition, which includes the following components in parts by weight:
example 4
This example provides an infant formula containing a protein composition, the infant formula comprising the following components in parts by weight:
wherein the edible vegetable blend oil is a mixture of corn oil, rapeseed oil, coconut oil and sunflower seed oil according to the weight ratio of 9: 8: 2: 1;
the compound nutrient enhancer comprises the following components in percentage by weight: vitamin A0.65%, vitamin D0.4%, vitamin E2.85%, and vitamin K10.005% and vitamin B10.06%, vitamin B20.01%, vitamin B60.06 percent and vitamin B120.0002%, vitamin C14%, 0.3% of pantothenic acid, 0.01% of folic acid, 0.4% of nicotinamide, 0.0018% of biotin, 4.5% of inositol, 3.7% of taurine, 0.8% of L-carnitine, 10.5% of choline chloride, 10% of sodium chloride, 24% of potassium chloride, 8.1% of magnesium sulfate, 2.8% of zinc gluconate, 4.0% of ferrous gluconate, 0.2% of copper gluconate, 0.007% of potassium iodide, 0.0031% of sodium selenite, 0.017% of manganese sulfate, 4.1% of calcium hydrogen phosphate and the balance of lactose.
The present embodiment also provides a preparation method of the infant formula milk powder, which comprises the following steps:
1. identification and selection of raw milk
By screening genes of the dairy cows, the dairy cows only producing A2 type beta-casein are selected to be fed and cultured in groups, and raw milk is collected.
2. Examination of raw milk
All indexes and inspection methods are implemented according to GB 19301-2010 national food safety Standard raw milk.
3. Milk cleanser
155 parts of raw milk by weight is purified by a milk purifier, and the impurity degree is less than 0.25 ppm.
4. Pasteurization
Harmful microorganisms (including pathogenic bacteria) in raw milk are killed by a pasteurization machine, the quality of the raw milk is ensured not to change in the cold storage process, the sterilization temperature is 80-85 ℃, and the sterilization time is 15 seconds, so that the bacteria in the raw milk reach the specified range.
5. Ingredients
And 5.1, checking and accepting the auxiliary materials and warehousing the auxiliary materials according to relevant regulations of laboratories and methods for product protection, identification, transportation and warehouse management.
5.2, removing external packages of various raw and auxiliary materials meeting the standard, namely desalted whey powder, whey protein powder I, whey protein powder II, whey protein powder III, lactose, fructo-oligosaccharide, phospholipid and the like, removing dust, purifying, conveying to a batching workshop, pouring into a batching powder bin according to the required amount of the formula, and feeding into a vacuum mixer from the powder bin for adding.
5.3, dissolving the compound nutrient enhancer in a special nutrient tank, adding proper water into the special nutrient tank according to the proportion of water to powder of not less than 8:1, pouring the mixture into the tank when the temperature is 30-50 ℃, and mixing the dissolved nutrient with pasteurized milk in a vacuum mixer.
5.4, dissolving calcium carbonate and sodium citrate in a special nutrient tank, adding proper water into the special nutrient tank according to the process requirement that the ratio of water to powder is not less than 8:1, pouring the mixture into the tank at the temperature of 45-60 ℃, and mixing the calcium carbonate and the sodium citrate after dissolving in a vacuum mixer with the pasteurized milk.
5.5, adding mode of edible plant blend oil: and (3) pumping the melted edible plant blend oil into an oil storage tank, stirring at the temperature of 45 ℃, and metering by an oil meter and then entering a vacuum mixing cycle.
5.6, adding fructo-oligosaccharide: and (3) putting the fructo-oligosaccharide powder into a vacuum mixer according to the formula requirements to be mixed with the pasteurized milk.
6. Homogenizing
Homogenizing the mixed materials under 160-210 bar to ensure product uniformity and improve product digestibility.
7. Vacuum concentrating
The homogenized material is put into a vacuum evaporator for reduced pressure concentration, most of water (about 60 percent) in the ingredient milk is removed, so that the product quality is facilitated, the production cost is reduced, and the sterilization and concentration are carried out through four-effect equipment. The sterilization temperature is 85-98 ℃, and the density of the concentrated milk is 1100-1200 kg/m3。
8. Spray drying
The concentrated material is made to pass through high pressure pump to make the concentrated milk enter the drying tower through preheater to exchange heat with hot air, the concentrated milk is dried into powder, and the pressure of the high pressure pump is controlled at 150-250 bar. The production process is stable, the air inlet temperature is controlled between 160 ℃ and 200 ℃, and the air exhaust temperature is controlled between 65 ℃ and 90 ℃.
9. Fluidized bed cooling
The temperature of the milk powder from the drying tower is reduced to 10-30 ℃ by the fluidized bed.
10. Inspection of semi-finished product
And (4) sampling the sieved powder to obtain a semi-finished product, carrying out physical and chemical and microbial inspection, and entering the next procedure under the qualified condition.
11. Premixing
According to the addition amount of the formula, the arachidonic acid, the docosahexaenoic acid, the lactoferrin and the casein phosphopeptide are premixed with a part of semi-finished products, and the premix needs to be stored in a sealing way.
12. Mixing
And (4) mixing the semi-finished product with the premix in the step (11) according to the addition amount of the formula to obtain a finished formula milk powder product.
13. Finished product package
The oxygen content in the package of the bagged product is less than 2.5 percent. The oxygen content in the package of the canned product should be less than 5.0%.
The technical indexes of the infant formula milk powder prepared by the embodiment are shown in table 1;
TABLE 1 comparison of technical and breast milk indices for infant formula of example 4
Example 5
This example provides an infant formula containing a protein composition, the infant formula comprising the following components in parts by weight:
wherein the edible vegetable blend oil is a mixture of corn oil, rapeseed oil, coconut oil and sunflower seed oil according to the weight ratio of 9: 8: 2: 1;
the compound nutrient enhancer comprises the following components in percentage by weight: 0.91% of vitamin A, 0.5% of vitamin D, 3.4% of vitamin E and vitamin K10.008% of vitamin B10.1% of vitamin B20.015 percent and vitamin B60.1% of vitamin B120.0004%, vitamin C14%, pantothenic acid 0.23%, folic acid 0.02%, nicotinamide 0.5%, biotin 0.003%, inositol 5%, taurine 5%, L-carnitine 1.1%, choline chloride 12%, sodium chloride 7%, potassium chloride 21%, magnesium sulfate 6%, zinc gluconate 2.2%, ferrous gluconate 7.5%, copper gluconate 0.3%, potassium iodide 0.0015%, sodium selenite 0.0045%, calcium hydrogen phosphate 6%, and lactose in balance.
The infant formula of this example was prepared in the same manner as in example 4.
The technical indexes of the infant formula milk powder prepared by the embodiment are shown in table 2;
TABLE 2 comparison of technical index and breast milk index of infant formula in example 5
Example 6
This example provides an infant formula containing a protein composition, the infant formula comprising the following components in parts by weight:
wherein the edible vegetable blend oil is a mixture of corn oil, rapeseed oil, coconut oil and sunflower seed oil according to the weight ratio of 9: 8: 2: 1;
the formulationThe nutrition enhancer comprises the following components in percentage by weight: vitamin A0.65%, vitamin D0.4%, vitamin E2.85%, and vitamin K10.005% and vitamin B10.06 percent and vitamin B20.01 percent of vitamin B60.06 percent and vitamin B120.0002%, vitamin C14%, 0.3% of pantothenic acid, 0.01% of folic acid, 0.4% of nicotinamide, 0.0018% of biotin, 4.5% of inositol, 3.7% of taurine, 0.8% of L-carnitine, 10.5% of choline chloride, 10% of sodium chloride, 24% of potassium chloride, 8.1% of magnesium sulfate, 2.8% of zinc gluconate, 4.0% of ferrous gluconate, 0.2% of copper gluconate, 0.007% of potassium iodide, 0.0031% of sodium selenite, 0.017% of manganese sulfate, 4.1% of calcium hydrogen phosphate and the balance of lactose.
The infant formula of this example was prepared in the same manner as in example 4.
The technical indexes of the infant formula milk powder prepared by the embodiment are shown in table 3;
TABLE 3 comparison of technical index and breast milk index of infant formula in example 6
Comparative example 1
This comparative example provides an infant formula containing a protein composition, differing from example 4 only in that: the protein composition is different;
specifically, the protein composition comprises the following components (containing no casein phosphopeptide and hydrolyzed whey protein, and containing no A2 type beta-casein in raw milk) in parts by weight:
comparative example 2
This comparative example provides an infant formula containing a protein composition, differing from example 4 only in that: the protein composition is different;
specifically, the protein composition comprises the following components in parts by weight (different formulas):
comparative example 3
This comparative example provides an infant formula containing a protein composition, differing from example 4 only in that: the protein composition is different;
specifically, raw milk with the A2 type beta-casein content of 0.9-2.5 percent in the protein composition is replaced by raw milk without A2 type beta-casein, casein phosphopeptide is replaced by casein powder, and whey protein powder III with the hydrolyzed whey protein content of 52-85 percent and whey protein powder I with the alpha-lactalbumin content of 34-70 percent are replaced by whey protein powder 80.
Test example 1
This test example performed a protein in vitro simulated digestibility comparison test on the protein composition of example 1, the infant formulas of examples 4-6 and comparative examples 1-3, and two other commercially available infant formulas; the method comprises the following specific steps:
(1) digestion of stomach in vitro: prepare 100mL milk sample, preheat in 37 deg.C water bath for 10 min. HCI with a concentration of 1mol/L is added to adjust the pH value to 3, and 0.04g of pepsin and 0.06g of chymosin are added and stirred continuously. Hydrolysis L h, adjusting the pH to 7 with NaoH at L mol/L.
(2) Digestion of the intestine in vitro: 0.1g of trypsin is weighed and added into the hydrolysate and is continuously stirred for 2 hours. After the time, the inactivation is carried out in a boiling water bath for 5 min. And cooling, placing in a refrigerator, and testing.
(3) Determination of digestibility: 10mL of digested sample is taken, 10% trichloroacetic acid with the same volume is added to precipitate protein, and the protein is centrifuged at 4000r/min for 10 min. Taking the supernatant, and measuring the content of the soluble protein by Kjeldahl nitrogen determination.
The test results are shown in table 4, wherein the protein digestibility is calculated as follows:
TABLE 4 protein digestibility of examples 1, 4-6, 1-3 and commercial conventional infant formulas
| Sample (I) | Digestibility (%) |
| Example 1 | 84.09±0.36a |
| Example 4 | 86.35±0.33a |
| Example 5 | 86.64±0.49a |
| Example 6 | 88.75±0.52a |
| Comparative example 1 | 74.85±0.65b |
| Comparative example 2 | 76.32±0.27b |
| Comparative example 3 | 70.09±0.79c |
| Commercially available infant formula 1 | 71.79±0.33c |
| Commercially available infant formula 2 | 72.65±0.48c |
Note: a. b and c in different columns show significant differences (P < 0.05)
As shown in Table 4, the in vitro protein digestibility of the infant formulas of examples 4-6 was significantly higher than that of the common infant formula sold in the market; the protein composition of example 1 is more easily absorbed and utilized by the body than conventional whey protein and casein.
Although the invention has been described in detail hereinabove by way of general description, specific embodiments and experiments, it will be apparent to those skilled in the art that many modifications and improvements can be made thereto based on the invention. Accordingly, such modifications and improvements are intended to be within the scope of the invention as claimed.
Claims (10)
1. A protein composition comprising casein, whey protein, milk fat globule membrane protein, and hydrolyzed protein;
wherein the mass ratio of casein to lactalbumin to milk fat globule membrane protein to hydrolyzed protein is 15-21: 11-20: 0.5-3: 4-10;
the casein is A2 type beta-casein; the whey protein consists of alpha-lactalbumin and lactoferrin in a mass ratio of 10-17: 0.5-3; the hydrolyzed protein consists of hydrolyzed whey protein and casein phosphopeptides in a mass ratio of 2-8: 1-3.
2. The protein composition according to claim 1, wherein the β -casein of type a2 is added in a form including but not limited to raw milk, preferably raw milk, the content of β -casein of type a2 in the raw milk being 0.9% to 2.5%;
and/or the alpha-lactalbumin is added in the form of whey protein powder I, and the content of the alpha-lactalbumin in the whey protein powder I is 34-70%;
and/or the milk fat globule membrane protein is added in the form of whey protein powder II, and the content of the milk fat globule membrane protein in the whey protein powder II is 8-20%;
and/or the hydrolyzed whey protein is added in the form of whey protein powder III, wherein the content of the hydrolyzed whey protein in the whey protein powder III is 52-85%;
and/or the purity of the lactoferrin is 80-98%;
and/or the purity of the casein phosphopeptide is 20-96%.
3. The protein composition of claim 2, wherein the protein composition comprises the following components in parts by weight:
preferably, the protein composition comprises the following components in parts by weight:
more preferably, the protein composition comprises the following components in parts by weight:
4. use of the protein composition of any one of claims 1 to 3 for the preparation of a food, health food or pharmaceutical product; preferably, the food product comprises milk powder, more preferably infant formula.
5. An infant formula containing a protein composition comprising a protein composition according to any one of claims 1 to 3;
preferably, the weight percentage of the protein composition in the infant formula is 18-66%;
more preferably, the weight percentage of the protein composition in the infant formula is 22-60%;
most preferably, the protein composition is present in the infant formula in an amount of 25 to 56% by weight.
6. The infant formula of claim 5, further comprising an adjuvant; the auxiliary materials comprise edible plant blend oil, lactose, fructo-oligosaccharide, calcium carbonate, sodium citrate, a compound nutrition enhancer, arachidonic acid and docosahexaenoic acid;
wherein the edible vegetable blend oil is selected from at least two of 1, 3-dioleoyl-2-palmitic acid triglyceride, soybean oil, rapeseed oil, sunflower seed oil, corn oil, palm kernel oil and coconut oil; preferably, the mixture is corn oil, rapeseed oil, coconut oil and sunflower seed oil in a weight ratio of 8-10: 7-9: 1-3: 1;
the compound nutrition enhancer comprises the following components in percentage by weight: 20-40% of compound vitamin, 30-60% of compound mineral and 10-25% of lactose.
7. Infant formula according to claim 5 or 6, characterized in that it comprises the following components in parts by weight:
the protein composition comprises 140-440 parts of raw milk with A2 type beta-casein content of 0.9-2.5%, 1-5 parts of lactalbumin powder I with alpha-lactalbumin content of 34-70%, 0.5-4 parts of lactalbumin powder II with milk fat globule membrane protein content of 8-20%, 0.1-3 parts of lactalbumin powder III with hydrolyzed lactalbumin content of 52-85%, 0.05-0.4 part of lactoferrin with purity of 80-98%, and 0.1-0.4 part of casein phosphopeptide with purity of 20-96%;
the edible vegetable blend oil is a mixture of corn oil, rapeseed oil, coconut oil and sunflower seed oil according to a weight ratio of 8-10: 7-9: 1-3: 1;
the compound nutrition enhancer comprises the following components in percentage by weight: 0.4 to 1.4 percent of vitamin A, 0.3 to 1.3 percent of vitamin D, 2 to 5 percent of vitamin E and K10.003-0.02 percent of vitamin B10.01 to 0.2 percent of vitamin B20.008 to 0.4 percent of vitamin B60.02-0.2 percent of vitamin B120.0001-0.001%, 10-25% of vitamin C, 0.1-1% of pantothenic acid, 0.005-0.05% of folic acid, 0.2-1% of nicotinamide, 0.0010-0.005% of biotin, 2-10% of inositol, 2-10% of taurine, 0.5-2% of L-carnitine, 5-20% of choline chloride, 5-20% of sodium chloride, 10-30% of potassium chloride, 2-15% of magnesium sulfate, 1-5% of zinc gluconate, 2-15% of ferrous gluconate, 0.1-0.6% of copper gluconate, 0.001-0.02% of potassium iodide, 0.001-0.01% of sodium selenite, 0-0.1% of manganese sulfate, 3-15% of calcium hydrogen phosphate and the balance of lactose.
8. Infant formula according to claim 7, characterized in that it comprises the following components in parts by weight:
wherein the protein composition comprises 150-380 parts of raw milk with A2 type beta-casein content of 0.9-2.5%, 1.5-4.5 parts of whey protein powder I with alpha-lactalbumin content of 34-70%, 1-3 parts of whey protein powder II with milk fat globule membrane protein content of 8-20%, 0.4-2.5 parts of whey protein powder III with hydrolyzed whey protein content of 52-85%, 0.1-0.3 part of lactoferrin with purity of 80-98%, and 0.15-0.4 part of casein phosphopeptide with purity of 20-96%;
the edible plant blend oil and the compound nutrition enhancer are the same as in claim 7.
9. Infant formula according to claim 8, characterized in that it comprises the following components in parts by weight:
wherein the protein composition comprises 170-370 parts of raw milk with A2 type beta-casein content of 0.9-2.5%, 2-4.5 parts of whey protein powder I with alpha-lactalbumin content of 34-70%, 1.5-2.5 parts of whey protein powder II with milk fat globule membrane protein content of 8-20%, 0.5-2 parts of whey protein powder III with hydrolyzed whey protein content of 52-85%, 0.15-0.3 part of lactoferrin with purity of 80-98%, and 0.15-0.3 part of casein phosphopeptide with purity of 20-96%;
the edible plant blend oil and the compound nutrition enhancer are the same as in claim 7.
10. A method of preparing an infant formula according to any one of claims 5 to 9, comprising the steps of:
1) mixing desalted whey powder, edible vegetable blend oil, whey protein powder I, whey protein powder II, whey protein powder III, lactose, fructo-oligosaccharide, phospholipid, calcium carbonate, sodium citrate, compound nutrition enhancer and raw milk, homogenizing, vacuum concentrating, and spray drying to obtain semi-finished product;
2) adding arachidonic acid, docosahexaenoic acid, lactoferrin and casein phosphopeptide into the semi-finished product, and mixing uniformly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010831837.6A CN111990462A (en) | 2020-08-18 | 2020-08-18 | Infant formula containing protein composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010831837.6A CN111990462A (en) | 2020-08-18 | 2020-08-18 | Infant formula containing protein composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111990462A true CN111990462A (en) | 2020-11-27 |
Family
ID=73473841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010831837.6A Pending CN111990462A (en) | 2020-08-18 | 2020-08-18 | Infant formula containing protein composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111990462A (en) |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113040227A (en) * | 2021-04-30 | 2021-06-29 | 南昌市傲龙食品有限公司 | Milk powder using A2 milk source for promoting growth and height development of children |
| CN114208896A (en) * | 2021-12-24 | 2022-03-22 | 光明乳业股份有限公司 | Novel infant formula milk powder with optimized protein composition and preparation method thereof |
| CN115067396A (en) * | 2022-06-30 | 2022-09-20 | 北京三元食品股份有限公司 | Infant formula powder and preparation method thereof |
| CN115191604A (en) * | 2021-07-27 | 2022-10-18 | 黑龙江飞鹤乳业有限公司 | Nutritional composition, food containing nutritional composition and application of nutritional composition |
| CN115500398A (en) * | 2021-06-23 | 2022-12-23 | 黑龙江飞鹤乳业有限公司 | Formula milk product rich in β-casein and preparation method thereof |
| CN115530283A (en) * | 2022-09-29 | 2022-12-30 | 黑龙江飞鹤乳业有限公司 | Protein compositions |
| CN116076739A (en) * | 2022-11-30 | 2023-05-09 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
| CN116114767A (en) * | 2023-03-17 | 2023-05-16 | 内蒙古伊利实业集团股份有限公司 | Dairy products and their use in the preparation of anti-inflammatory products |
| CN116172191A (en) * | 2023-03-17 | 2023-05-30 | 内蒙古伊利实业集团股份有限公司 | Nutritional composition and its application in preparing anti-inflammatory products |
| CN116235880A (en) * | 2023-03-17 | 2023-06-09 | 内蒙古伊利实业集团股份有限公司 | Application of protein complex in preparing formula food with anti-enteritis and/or intestinal barrier integrity protection functions |
| CN116250570A (en) * | 2022-11-23 | 2023-06-13 | 内蒙古伊利实业集团股份有限公司 | A kind of infant formula milk powder and preparation method thereof |
| CN116268098A (en) * | 2021-12-21 | 2023-06-23 | 内蒙古蒙牛乳业（集团）股份有限公司 | A2β -casein milk and preparation method and application thereof |
| CN116268099A (en) * | 2021-12-21 | 2023-06-23 | 内蒙古蒙牛乳业（集团）股份有限公司 | Functional milk for improving immunity and preparation method and application thereof |
| WO2023142838A1 (en) * | 2022-01-25 | 2023-08-03 | 内蒙古伊利实业集团股份有限公司 | Method for improving digestion performance for protein in food, and protein composition and food containing same |
| CN119817811A (en) * | 2025-03-17 | 2025-04-15 | 内蒙古蒙牛乳业（集团）股份有限公司 | Nutritional composition and use thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013174306A1 (en) * | 2012-05-24 | 2013-11-28 | 浙江康诺邦健康产品有限公司 | Infant formula milk powder and preparation method thereof |
| CN104012657A (en) * | 2014-05-21 | 2014-09-03 | 澳优乳业（中国）有限公司 | Amino acid humanized infant formula milk powder and preparation method thereof |
| CN105053217A (en) * | 2015-09-14 | 2015-11-18 | 海普诺凯营养品有限公司 | Infant formula ewe milk powder and production method thereof |
| CN109662150A (en) * | 2018-12-26 | 2019-04-23 | 光明乳业股份有限公司 | A kind of breast milk protein compositions and the babies ' formula milk powder containing it |
| CN109874870A (en) * | 2019-01-25 | 2019-06-14 | 上海花冠营养乳品有限公司 | A kind of infant milk powder of simulation breast milk proteins composition and immune function |
-
2020
- 2020-08-18 CN CN202010831837.6A patent/CN111990462A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013174306A1 (en) * | 2012-05-24 | 2013-11-28 | 浙江康诺邦健康产品有限公司 | Infant formula milk powder and preparation method thereof |
| CN104012657A (en) * | 2014-05-21 | 2014-09-03 | 澳优乳业（中国）有限公司 | Amino acid humanized infant formula milk powder and preparation method thereof |
| CN105053217A (en) * | 2015-09-14 | 2015-11-18 | 海普诺凯营养品有限公司 | Infant formula ewe milk powder and production method thereof |
| CN109662150A (en) * | 2018-12-26 | 2019-04-23 | 光明乳业股份有限公司 | A kind of breast milk protein compositions and the babies ' formula milk powder containing it |
| CN109874870A (en) * | 2019-01-25 | 2019-06-14 | 上海花冠营养乳品有限公司 | A kind of infant milk powder of simulation breast milk proteins composition and immune function |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113040227A (en) * | 2021-04-30 | 2021-06-29 | 南昌市傲龙食品有限公司 | Milk powder using A2 milk source for promoting growth and height development of children |
| CN115500398A (en) * | 2021-06-23 | 2022-12-23 | 黑龙江飞鹤乳业有限公司 | Formula milk product rich in β-casein and preparation method thereof |
| CN115500398B (en) * | 2021-06-23 | 2024-05-28 | 黑龙江飞鹤乳业有限公司 | Formulated dairy product rich in beta-casein and preparation method thereof |
| CN115191604A (en) * | 2021-07-27 | 2022-10-18 | 黑龙江飞鹤乳业有限公司 | Nutritional composition, food containing nutritional composition and application of nutritional composition |
| CN116268099A (en) * | 2021-12-21 | 2023-06-23 | 内蒙古蒙牛乳业（集团）股份有限公司 | Functional milk for improving immunity and preparation method and application thereof |
| CN116268098B (en) * | 2021-12-21 | 2024-05-17 | 内蒙古蒙牛乳业（集团）股份有限公司 | A2β -casein milk and preparation method and application thereof |
| CN116268099B (en) * | 2021-12-21 | 2024-05-10 | 内蒙古蒙牛乳业（集团）股份有限公司 | Functional milk for improving immunity and preparation method and application thereof |
| CN116268098A (en) * | 2021-12-21 | 2023-06-23 | 内蒙古蒙牛乳业（集团）股份有限公司 | A2β -casein milk and preparation method and application thereof |
| CN114208896A (en) * | 2021-12-24 | 2022-03-22 | 光明乳业股份有限公司 | Novel infant formula milk powder with optimized protein composition and preparation method thereof |
| CN116530575A (en) * | 2022-01-25 | 2023-08-04 | 内蒙古伊利实业集团股份有限公司 | Method for improving protein digestibility in food, protein composition and food containing same |
| WO2023142838A1 (en) * | 2022-01-25 | 2023-08-03 | 内蒙古伊利实业集团股份有限公司 | Method for improving digestion performance for protein in food, and protein composition and food containing same |
| CN115067396A (en) * | 2022-06-30 | 2022-09-20 | 北京三元食品股份有限公司 | Infant formula powder and preparation method thereof |
| CN115530283B (en) * | 2022-09-29 | 2024-01-26 | 黑龙江飞鹤乳业有限公司 | Protein composition |
| CN115530283A (en) * | 2022-09-29 | 2022-12-30 | 黑龙江飞鹤乳业有限公司 | Protein compositions |
| CN116250570A (en) * | 2022-11-23 | 2023-06-13 | 内蒙古伊利实业集团股份有限公司 | A kind of infant formula milk powder and preparation method thereof |
| CN116076739A (en) * | 2022-11-30 | 2023-05-09 | 内蒙古伊利实业集团股份有限公司 | Composition and application thereof |
| CN116235880A (en) * | 2023-03-17 | 2023-06-09 | 内蒙古伊利实业集团股份有限公司 | Application of protein complex in preparing formula food with anti-enteritis and/or intestinal barrier integrity protection functions |
| CN116172191A (en) * | 2023-03-17 | 2023-05-30 | 内蒙古伊利实业集团股份有限公司 | Nutritional composition and its application in preparing anti-inflammatory products |
| CN116114767A (en) * | 2023-03-17 | 2023-05-16 | 内蒙古伊利实业集团股份有限公司 | Dairy products and their use in the preparation of anti-inflammatory products |
| CN119817811A (en) * | 2025-03-17 | 2025-04-15 | 内蒙古蒙牛乳业（集团）股份有限公司 | Nutritional composition and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111990462A (en) | Infant formula containing protein composition and preparation method thereof | |
| CN106721843B (en) | Double-bacterial protein solid beverage | |
| CN110786388A (en) | Milk powder for promoting growth of children and preparation method thereof | |
| CN105614898B (en) | A kind of ocean compound protein powder and preparation method thereof containing oyster peptide | |
| CN110074188A (en) | A kind of baby formula milk powder and preparation method thereof adding human milk oligosaccharides | |
| CN107712050A (en) | One kind addition sialic acid and digestible premature labor baby milk powder and preparation method thereof | |
| CN112075504A (en) | Infant formula milk powder for enhancing immunity | |
| CN107668211A (en) | A kind of infant formula goat milk powder for strengthening immunologic function and preparation method thereof | |
| CN111067104A (en) | Composite probiotic infant formula milk powder and preparation method thereof | |
| CN116172191B (en) | Nutritional composition and its application in preparing anti-inflammatory products | |
| CN103271166A (en) | Soybean whey composite powder and preparation method thereof | |
| CN110074189A (en) | A kind of infant's diatery supplement and preparation method thereof adding human milk oligosaccharides | |
| CN113841740A (en) | Sialic acid-containing infant formula milk powder and preparation method thereof | |
| CN113796419A (en) | A kind of formula sheep milk powder for improving immunity of children and preparation method thereof | |
| CN113331256A (en) | Formula sheep milk powder capable of promoting sleep and preparation method thereof | |
| CN112471260A (en) | Organic formula milk powder for improving human immunity and preparation method thereof | |
| CN112715672A (en) | Oligosaccharide mother-emulsified infant formula milk and preparation method thereof | |
| CN111937966A (en) | Formula milk powder capable of reducing blood fat and preparation method thereof | |
| CN111642566A (en) | Goat milk powder beneficial to children's height and intelligence development | |
| CN110999984A (en) | Hypoallergenic infant formula milk powder and preparation method thereof | |
| CN111528474A (en) | A kind of preparation method of puerarin-vitamin-whey protein three-dimensional gel nutritional product | |
| CN117481199A (en) | Premature/low birth weight infant food for promoting growth and development, and preparation method and application thereof | |
| CN1493204A (en) | Manufacturing method of polypeptide calf milk powder substitute | |
| CN113729211A (en) | Composition and preparation method and application thereof | |
| CN114145356B (en) | Formula milk powder capable of improving immune response and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201127 |